The EVO ICL for Moderate Myopia: Results from the US FDA Clinical Trial.

Published in: Clinical ophthalmology (Auckland, N.Z.) (2022)

EVO ICL lenses demonstrated accuracy, predictability and stability of refractive correction with achievement of high levels of UDVA and an excellent safety profile for patients with moderate myopia with or without astigmatism.

Keyphrases

clinical trial
high intensity
cataract surgery
optic nerve
open label
phase ii